newsmetry
rusign inget started
macro

Kiniksa Q3 2026 revenue rises 58% to $285.97 million, net income up

Kiniksa Pharmaceuticals posted Q3 2026 revenue of $285.97 million, up 58.1%, with net income of $47.35 million, according to TradingView.

published on Newsmetry
original source published

the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →

Newsmetry newsroom

what happened

According to TradingView, Kiniksa Pharmaceuticals International recorded third-quarter 2026 revenue of $285.97 million, 58.1% higher than a year earlier. Net income climbed to $47.35 million, and diluted earnings per share rose to $0.56. The main driver was a larger number of patients receiving ARCALYST.

The company also updated its pipeline. The pivotal Phase 3 PASTORALE trial of KPL-387 has started enrolling and dosing patients, with results expected in the second half of 2027. Sales and marketing spending increased because of broader promotion, including a direct-to-consumer campaign. In June 2026, the FDA approved Samsung Biologics as the replacement manufacturing partner for ARCALYST.

why it matters

For investors, the fast growth in revenue and profit matters, along with the timing of key trials that will shape the company's outlook. The figures come from documents filed with the SEC.

market impact

Kiniksa shares (KNSA): strong results support investor interest in the stock

  • Kiniksa shares (KNSA) pressure up — faster revenue and profit growth in the third quarter supports demand for the stock

tags

EarningsStockUnited States

instruments

KNSA

sources

  1. Kiniksa Pharmaceuticals 3Q 2026: Revenue $285.97M, Net income $47.35M, EPS $0.56— 10-Q Summary — TradingView, 27 October 2026 at 20:41 UTC
  2. ExlService 3Q 2026: Revenue $633.96M, Net income $68.77M, EPS $0.45— 10-Q Summary — TradingView, 27 October 2026 at 20:51 UTC
  3. IQVIA 3Q 2026: Revenue $4.43B, Net income $352M, EPS $2.1— 10-Q Summary — TradingView, 27 October 2026 at 21:11 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.

get stories in real time ↗

related stories